Dr. Choueiri on the Biology of the CABOSUN Trial for RCC

Toni K. Choueiri, MD
Published: Monday, Aug 21, 2017



Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 


Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the findings of the CABOSUN trial for patients with metastatic renal cell carcinoma (mRCC).

The CABOSUN trial investigated cabozantinib (Cabometyx) versus sunitinib (Sutent) in patients with mRCC.

According to Choueiri, it is interesting to see that something that makes sense biologically was able translate to clinical outcomes. Cabozantinib appeared to be superior to sunitinib, which is what was seen in the results of the study, explains Choueiri.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x